



29 April 2026

ASX ANNOUNCEMENT

Cleansing Statement

CONNEQT Health Limited (ASX: CQT) (“CONNEQT” or “the Company”) advises that on 29 April 2026, it issued a total of 31,155,555 Fully Paid Ordinary Shares and 2,000,000 Convertible Notes without disclosure to the recipient under Part 6D.2 of the Corporations Act 2001 (Cth) (the **Corporations Act**).

The Company hereby gives notice under Section 708A(5)(e) of the Corporations Act, and for all other purposes, that:

- (a) the company has issued the Securities without disclosure to the recipient under Part 6D.2 of the Corporations Act;
- (b) as at the date of this notice, the Company has complied with the provisions of:
 - a. Chapter 2M of the Corporations Act as they apply to the Company; and
 - b. Sections 674 and 674A of the Corporations Act as they apply to the Company; and
- (c) as at the date of this notice, there is no information:
 - a. that has been excluded from a continuous disclosure notice in accordance with the ASX Listing Rules; and
 - b. that investors and their professional advisers would reasonably require for the purpose of making an information assessment of:
 - i. the assets and liabilities, financial position and performance, profits and losses and prospects of the body; or
 - ii. the rights and liabilities attaching to the relevant securities.

to the extent to which it is reasonable for investors and their professional advisers to expect to find the information in a disclosure document.

Approved by the Board of Directors and Released by the Company Secretary

- ENDS -

C O N N E Q T
Health

CONNEQT Health, LTD.
ASX: CQT

Info@conneqthealth.com
conneqthealth.com

Suite 301, 55 Lime St
Sydney NSW 2000
Australia

+61 2 9874 8761



For more information, please contact:

Investor Relations

Rod Hinchcliffe

rod.hinchcliffe@mcpartners.com.au

Media Relations

Melissa Hamilton

melissa.hamilton@mcpartners.com.au

About CONNEQT HEALTH

CONNEQT Health's mission is to increase longevity through medical technology advancements in vascular health. The Company's suite of products includes medical and home health devices and digital solutions for hypertension, cardiovascular disease, and other vascular health disorders - all based on the Company's market-leading SphygmoCor® vascular biomarker technology. CONNEQT Health is listed on the Australian Stock Exchange ("ASX: CQT").